RESUMEN
Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated viral vaccines. This will help key stakeholders assess potential safety issues and understand the benefit-risk of such vaccines. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed live-attenuated viral vaccines.
Asunto(s)
Evaluación Preclínica de Medicamentos/normas , Vacunas Atenuadas/efectos adversos , Vacunas Virales/efectos adversos , Vacunas contra la COVID-19/efectos adversos , Vacunas contra la COVID-19/farmacología , Evaluación Preclínica de Medicamentos/métodos , Humanos , Medición de Riesgo , Sociedades Científicas , Vacunas Atenuadas/farmacología , Vacunas Virales/farmacologíaRESUMEN
Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO, formerly the Viral Vector Vaccine Safety Working Group, V3SWG) working group has prepared a standardized template to describe the key considerations for the benefit-risk assessment of viral vector vaccines. This will facilitate key stakeholders to anticipate potential safety issues and interpret or assess safety data. This would also help improve communication and public acceptance of licensed viral vector vaccines.